





CORE PROTOCOL

Staphylococcus aureus Network Adaptive Platform trial (SNAP)

Le fardeau des bactériémies à *Staphylococcus aureus*

Bloodstream infections caused by meticillin-resistant and meticillin-susceptible *Staphylococcus aureus*, EU/EEA, 2005–2018 (n = 258,448)



Verway et al. J Clin Microbiol 2022

Cagliotti C et al. Eurosurv 2021

Efficacy and safety of an early oral switch in low-risk *Staphylococcus aureus* bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

*Achim J Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, José Miguel Cisneros, M Dolores Navarro, Gerd Fätkenheuer, Norma Jung, Siegbert Rieg, Raphaël Lepeule, Laetitia Coutte, Louis Bernard, Adrien Lemaignen, Katrin Kösters, Colin R MacKenzie, Alex Soriano, Stefan Hagel, Bruno Fantin, Matthieu Lafaurie, Jean-Philippe Talarmin, Aurélien Dinh, Thomas Guimard, David Boutoille, Tobias Welte, Stefan Reuter, Jan Kluytmans, Maria Luisa Martin, Emmanuel Forestier, Hartmut Stocker, Virginie Vitrat, Pierre Tattevin, Anna Rommerskirchen, Marion Noret, Anne Adams, Winfried V Kern, Martin Hellmich, Harald Seifert, for the SABATO study group**


Supplementary Table S1 (Sites and enrolment)



Country, Principal Investigator and number of participants enrolled per site.

Country	Site	Principal Investigator	Participants enrolled
Germany	Cologne	Gerd Fätkenheuer/Achim Kaasch	22
Germany	Freiburg	Winfried Kern	15
Germany	Düsseldorf	Achim Kaasch	8
Germany	Krefeld	Katrin Kösters	8
Germany	Jena	Mathias Pletz	6
Germany	Hannover	Tobias Welte	4
Germany	Leverkusen	Stefan Reuter	4
Germany	Berlin	Keikawus Arasteh	3
Germany	Frankfurt	Christoph Stephan	2
Germany	Lübeck	Jan Rupp	1
Spain	Sevilla	Jesus Rodriguez-Baño	29
Spain	Sevilla	Jose-Miguel Cisneros	24
Spain	Barcelona	Alex Soriano	7
Spain	Palma de Mallorca	Luisa Martin	4
The Netherlands	Breda	Jan Kluytmans	4
The Netherlands	Utrecht	Marc Bonten	2
The Netherlands	Utrecht	Anneloes Vlek	1
France	Paris	Raphael Lepeule	13
France	Tours	Louis Bernard	12
France	Paris	Bruno Fantin	6
France	Paris	Jean Michel Molina	6
France	Quimper	Jean-Philippe Talarmin	6
France	La Roche sur Yon	Marine Morrier	5
France	Nantes	David Boutoille	5
France	Paris	Elisabeth Rouveix Nordon	5
France	Chambéry	Emmanuel Forestier	4
France	Annecey	Virginie Vitrat	3
France	Grenoble	Jean Paul Stahl	1
France	Orléans	Laurent Hocqueloux	1
France	Rennes	Pierre Tattevin	1
France	St. Etienne	Frédéric Lucht	1

Critères inclusion:

- Hc + *S. aureus*
- Prélèvement <72h
- Patient OK





Silo	Antibiotic Backbone Domain	Adjunctive Treatment Domain	Early Oral Switch Domain
PSSA	(Flu)cloxacillin* Penicillin	No clindamycin* vs Clindamycin	Usual care* (<i>initial 2-6 week antibiotic backbone treatment course given intravenously</i>) versus early oral switch algorithm (<i>as detailed in the relevant DSA</i>)
MSSA	(Flu)cloxacillin* Cefazolin		
MRSA	Vancomycin/Daptomycin* vs Vancomycin/Daptomycin plus cefazolin		


Note that domains and interventions may be added or dropped during the life of the platform. This initial design is given only as an illustration of the trial's structure.

*=Comparator/control group

Visit Day	Day 1			Day 2	Day 5	Day 7	Day 14	Day 28	Day 42	D/C	Day 90
Eligibility screening	X										
Informed consent		X									
Randomization			X								
Baseline lab tests			X								
Collect blood cultures				X	X						
Collect data			X			X	X	X	X	X	X

Update SNAP worldwide

Update 22-12-2023



Update SNAP worldwide


Update 22-12-2023

91 sites in 8 regions globally

- **1861** in SNAP Platform
- **2116** in the SNAP Registry

European inclusions started end of October 2023 (NL, 2 sites)

- **19** inclusions (platform & registry)
- A lot of interest in EOS



Update SNAP Europe

- **Contracts AUS:** in place
- **Ethical submission in Europe (via CTIS):** full approval
- **News EU**
 - **Germany:** requested funding
adjunctive fosfomycin domain discussed in GTSC
 - **Sweden:** 2 fundings received
 - **Spain:** no funding available, discussions ongoing about joining in 2024
 - **France:** 2 fundings requests approved at first stage (LOI)
(2-stage calls, ANRS Rech-MIE & PHRC-N)

Etat du projet

Budget

- (1190 k€ pour 500 patients) x 2
- Budget RENARCI 100 k€ x 2

Faisabilité

- Gros succès !
- Possibilité de participation 'à la carte'
- Nécessité de sélectionner (16 centres si 1 financement, 32 si 2)
- Limite n°1 = inclusion < 72 h post prélèvement hémoc index
- Atouts: RENARCI (Nathalie Gastellier) + DRC Rennes (Mathilde Ouvrard)

Stratégie

- Double dépôt (dates limites et formats proches)
- Transparence => Financeur unique = DGOS
- Étude ancillaire pharmaco-éco Française (I Durand-Zaleski, L Kardas)
- Autres études randomisées en cours prioritaires (TEP-Star, Dalicath)
- Mettre le pied dans la porte pour étendre les projets Frenchies !